DK1303600T3 - Cellepermeable peptidinhibitorer fra JNK-signaltransduktionsvejen - Google Patents

Cellepermeable peptidinhibitorer fra JNK-signaltransduktionsvejen

Info

Publication number
DK1303600T3
DK1303600T3 DK00969730T DK00969730T DK1303600T3 DK 1303600 T3 DK1303600 T3 DK 1303600T3 DK 00969730 T DK00969730 T DK 00969730T DK 00969730 T DK00969730 T DK 00969730T DK 1303600 T3 DK1303600 T3 DK 1303600T3
Authority
DK
Denmark
Prior art keywords
signal transduction
transduction pathway
peptide inhibitors
cell permeable
permeable peptide
Prior art date
Application number
DK00969730T
Other languages
Danish (da)
English (en)
Inventor
Christophe Bonny
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Application granted granted Critical
Publication of DK1303600T3 publication Critical patent/DK1303600T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK00969730T 1999-10-12 2000-10-12 Cellepermeable peptidinhibitorer fra JNK-signaltransduktionsvejen DK1303600T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15877499P 1999-10-12 1999-10-12
US09/503,954 US6610820B1 (en) 1999-10-12 2000-02-14 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
PCT/IB2000/001538 WO2001027268A2 (en) 1999-10-12 2000-10-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Publications (1)

Publication Number Publication Date
DK1303600T3 true DK1303600T3 (da) 2009-01-12

Family

ID=26855384

Family Applications (3)

Application Number Title Priority Date Filing Date
DK00969730T DK1303600T3 (da) 1999-10-12 2000-10-12 Cellepermeable peptidinhibitorer fra JNK-signaltransduktionsvejen
DK07021046.3T DK1905830T3 (da) 1999-10-12 2000-10-12 Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen
DK07003426.9T DK1811033T3 (da) 1999-10-12 2000-10-12 Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK07021046.3T DK1905830T3 (da) 1999-10-12 2000-10-12 Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen
DK07003426.9T DK1811033T3 (da) 1999-10-12 2000-10-12 Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen

Country Status (12)

Country Link
US (5) US6610820B1 (de)
EP (5) EP1303600B1 (de)
JP (5) JP5490343B2 (de)
AT (3) ATE411388T1 (de)
AU (1) AU784845B2 (de)
CA (1) CA2387184C (de)
CY (2) CY1110422T1 (de)
DE (1) DE60040564D1 (de)
DK (3) DK1303600T3 (de)
ES (3) ES2383824T3 (de)
PT (2) PT1811033E (de)
WO (1) WO2001027268A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043083A (en) * 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP1301213B1 (de) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Mehrkomponentensysteme zur transport von biologischen wirkstoffen
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
US7803749B2 (en) 2002-01-09 2010-09-28 Xigen Sa Peptide inhibitors of MKK7 kinase binding to insulin binding proteins
EP3514238B1 (de) * 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
EP1713332A4 (de) * 2004-01-23 2010-08-18 Avi Biopharma Inc Antisense-oligomere und verfahren zur induktion von immuntoleranz und immunosuppression
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
EP1769802A1 (de) 2004-06-29 2007-04-04 St. Marianna University School of Medicine Nf&kappab-hemmer und entzündungshemmer und mittel zur verstärkung der steroid-wirkung
US20100256041A1 (en) * 2004-11-12 2010-10-07 Christophe Bonny Conjugate Molecule Compounds With Enhanced Cell Uptake Activity
EP1656951A1 (de) * 2004-11-12 2006-05-17 Xigen S.A. Konjugate mit verbesserter Zellaufnahme
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU2012203529B2 (en) * 2005-09-12 2016-01-07 Xigen Inflammation Ltd. Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
WO2007035553A2 (en) * 2005-09-15 2007-03-29 The Regents Of The University Of California Methods and compositions for detecting neoplastic cells
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
JPWO2008015841A1 (ja) * 2006-08-02 2009-12-17 梅澤　喜夫 キナーゼ阻害性融合タンパク質と医薬組成物
EP2074138A4 (de) * 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotektive peptidinhibitoren der ap-1-signalvermittlung und anwendungen davon
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
EP2170932A4 (de) 2007-06-20 2012-10-10 Phylogica Ltd Zusammensetzungen und anwendungen davon bei der behandlung von akutem atemnotsyndrom (ards) und damit assoziierten klinischen erkrankungen
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CN102365093A (zh) 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
WO2010151638A1 (en) 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
MX2014006399A (es) * 2011-11-30 2015-04-10 Xigen Inflammation Ltd Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197098A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2870085T3 (es) * 2013-06-26 2021-10-26 Xigen Inflammation Ltd Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016055160A2 (en) 2014-10-08 2016-04-14 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
US11672801B2 (en) 2016-10-19 2023-06-13 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
CN113730548B (zh) * 2020-05-14 2023-06-30 山东省科学院生物研究所 一种活性十肽在保护听觉毛细胞方面的应用
EP4545552A1 (de) * 2022-06-22 2025-04-30 Toagosei Co., Ltd. Trägerpeptidfragment und verwendung davon
DE102023203471A1 (de) * 2023-04-17 2024-10-17 Brose Fahrzeugteile Se & Co. Kommanditgesellschaft, Bamberg Mitnehmer für einen Seilfensterheber eines Kraftfahrzeugs
WO2025262278A1 (en) 2024-06-21 2025-12-26 Institut Pasteur A neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof
WO2025262307A2 (en) 2024-06-21 2025-12-26 Institut Pasteur Vhh suitable to vectorize molecules intracellularly

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195304B (it) * 1981-12-22 1988-10-12 Anic Spa Metodo per la preparazione di gem-diammino derivati n-monoacilati
IT1190389B (it) * 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IT1227907B (it) * 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
CA2135642C (en) * 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
US5880261A (en) 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP0897002A3 (de) 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, ein Protein mit einem JNK-bindendem Gebiet
CA2328457A1 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

Also Published As

Publication number Publication date
CA2387184C (en) 2014-02-11
EP1914310A2 (de) 2008-04-23
HK1111732A1 (en) 2008-08-15
EP1895005B1 (de) 2017-07-26
PT1811033E (pt) 2012-03-02
DK1811033T3 (da) 2012-05-07
EP1905830B1 (de) 2012-03-07
EP1303600A2 (de) 2003-04-23
EP1905830A1 (de) 2008-04-02
AU784845C (en) 2001-04-23
EP1811033A1 (de) 2007-07-25
EP1905830B8 (de) 2012-04-11
ATE541929T1 (de) 2012-02-15
AU7938200A (en) 2001-04-23
PT1303600E (pt) 2008-12-23
WO2001027268A3 (en) 2001-11-22
US6780970B2 (en) 2004-08-24
ES2383824T3 (es) 2012-06-26
ATE411388T1 (de) 2008-10-15
WO2001027268A2 (en) 2001-04-19
DK1905830T3 (da) 2012-07-02
ES2381206T3 (es) 2012-05-24
JP2015221833A (ja) 2015-12-10
CY1112587T1 (el) 2016-02-10
ES2313906T3 (es) 2009-03-16
JP2008024710A (ja) 2008-02-07
DE60040564D1 (de) 2008-11-27
JP2011155990A (ja) 2011-08-18
US20020127676A1 (en) 2002-09-12
US6610820B1 (en) 2003-08-26
ATE548455T1 (de) 2012-03-15
US20100216716A1 (en) 2010-08-26
EP1811033B1 (de) 2012-01-18
EP1914310A3 (de) 2008-05-07
HK1100958A1 (en) 2007-10-05
US20050043241A1 (en) 2005-02-24
EP1895005A1 (de) 2008-03-05
AU784845B2 (en) 2006-07-06
US20030220480A1 (en) 2003-11-27
JP2003511071A (ja) 2003-03-25
JP5490343B2 (ja) 2014-05-14
CY1110422T1 (el) 2015-04-29
EP1303600B1 (de) 2008-10-15
CA2387184A1 (en) 2001-04-19
JP2013081479A (ja) 2013-05-09

Similar Documents

Publication Publication Date Title
DK1303600T3 (da) Cellepermeable peptidinhibitorer fra JNK-signaltransduktionsvejen
DK1776958T5 (da) Celle-permeable peptidinhibitorer fra JNK signaltransduktionsvejen
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DE60041505D1 (de) Inzektizide proteinen von bacillus thuringiensis
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
PT951467E (pt) Heterociclos contendo azoto substituido como inibidores de cinase de proteina p38
DE50106823D1 (de) Schaltungsanordnung zum zerstörungsfreien, selbstnormierenden auslesen von mram-speicherzellen
NO20000097D0 (no) Isolerte dendrittcellemembranproteingener
DE60016629D1 (de) Ox(adi)azoly-hydroxamsäuren und ihre verwendung als prokollagen c-proteinase inhibitoren
DE60105771D1 (de) Indanderivate und ihre verwendung als zelladhäsionsinihibitoren
DE60305668D1 (de) Erhöhen des lesesignals in ferroelektrischen speichern
DE50006021D1 (de) Brennstoffzellenblock
DE60225739D1 (de) Lesen von Speicherzellen
DE60040505D1 (de) System zur Bestimmung der Empfindlichkeit des Leseverstärkers von DRAM-Speichern
EP1541677A4 (de) Neue proteine und verwendung davon
EP1802332A4 (de) Modifizierte hiv-1-hüllproteine
DE60235786D1 (de) Zell mit modifizierter Membran
FI961299A0 (fi) Cysteinproteinasinhibitorernas genteknologiska anvaendning foer foerhindrandet av vaevnadsdegeneration